Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancerEmily J. Faivre, Yu Shen, Joshua P. Plotnik et al.|Nature|2020Cited by 404
The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>Jun Chen, Steven W. Elmore, Sha Jin et al.|Molecular Cancer Therapeutics|2011Cited by 149